Osteoporosis and Chronic Kidney Disease
Dr. Reamer L. Bushardt, PharmD, PA-C, DFAAPA
“
• Appreciate keeping us engaged throughout the talk. Easy to follow. The information on Osteoporosis and CKD was super helpful and it was a great overview of important topics!
• Excellent information to help me provide best practice.
• Great info for us with who regularly care for CKD patients
• I feel my knowledge is increased and will impact every aspect of my life
• I work in Orthopedics and I learned some valuable information that I can incorporate into my practice.
• Session increased my knowledge on the topic. Will use knowledge gained in patient care.
• Some tools such as CKD affect on CVD risk will be useful in my practice.
• You are a great teacher. Your compassion comes through.
”
About This Course
Recorded April 24, 2025 and valid to April 24, 2028
Price $50 for 2 Hours
2025-02-19 Bushardt -Osteoporosis and Chronic Kidney Disease
Learning Objectives
Identify recent FDA drug communications, including but not limited to, labeling changes, warnings, new indications, new dosage forms and MedWatch alerts.
Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications.
Describe their adverse effects and drug interaction that may affect patient compliance.
Compare efficacy, dosage and cost to existing agent
Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.
Compare pharmacotherapy outcomes vs cost/benefit between newly approved agents and existing or lower cost agents.
Reamer L. Bushardt, PharmD, PA-C, DFAAPA
DFAAPA Professor, Provost and Vice President for Academic Affairs, Massachusetts General Hospital Institute for Health Professions, Mass General Brigham, Boston, MA. PA in Primary Care. Editor-in-Chief Emeritus, Journal of the American Academy of PAs. Principal Investigator Expansion of Practitioner Education in Substance Use Disorders Program, U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
Accreditation Information
PHARMACISTS :University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for pharmacists. On-demand courses provide HOME STUDY credit only.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS: Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). This credit is applicable to health professionals who may require pharmacology credit.
NURSE PRACTITIONERS: This course fulfills the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal as well as other Nurse Practitioner credentialing organizations. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE).
NURSES: University Learning Systems is Approved by the California Board of Registered Nursing, Provider Number CEP 11409, CE Broker: Arkansas, District of Columbia, Florida, Georgia, Kentucky, New Mexico, and West Virginia, Boards of Nursing.
PHYSICIANS: This CME program offers Category 2 credit.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive MAINPRO-M2 credits for participation in this activity.
PHYSICIAN ASSISTANTS: This CME program offers Category 2 credit.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval